Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

XOMA acquires Ixinity’s commercial payment and milestone rights in $9.6M

The deal expands XOMA's portfolio and could offer the company consistent cash flow and growth opportunities related to hemophilia B.

By Brian Buntz | March 31, 2023

XomaBiotech royalty aggregator XOMA (Nasdaq:XOMA) has acquired the commercial payment and part of the milestone rights to Ixinity (trenonacog alfa), a hemophilia B therapy originally from Aptevo Therapeutics (Nasdaq:APVO). The aggregator expects the move to bolster its royalty and milestone portfolio, potentially providing consistent cash flow and ramping up its royalty aggregation strategy.

The acquired asset, Ixinity, is now marketed by Medexus Pharmaceuticals (TSE:MDP) to control and prevent bleeding episodes and postoperative management in people with hemophilia B.

Aptevo sold Ixinity rights to Medexus Pharmaceuticals in 2020. The FDA first approved Ixinity in 2015.

A win-win deal

Brad Sitko

Brad Sitko

Brad Sitko, chief investment officer of XOMA, explained the company’s mission to Drug Discovery & Development, stating, “Our focus is to provide non-dilutive capital to biotech companies, so they can further innovation. Ixinity was not core to Aptevo’s focus on immuno-oncology (IO), and they were looking for a way to monetize the commercial payments so they can further their IO work.”

Sitko described the acquisition as a “win-win,” explaining that Aptevo now has capital for their development activities, and XOMA receives commercial payments. “The more cash flow XOMA receives, the more we can deploy to add additional partnered pre-commercial assets to our royalty and milestone portfolio,” he said.

XOMA focuses on offering non-dilutive capital to biotech firms to support their R&D efforts. Sitko expects the Ixinity acquisition allows Aptevo to concentrate on their immuno-oncology work while giving XOMA access to commercial payments and additional cash flow to strengthen their royalty and milestone portfolio.

The company will begin receiving a mid-single digit percentage payment stream on all Ixinity sales from Jan. 1, 2023, into the first quarter of 2035. The company will also be entitled to milestone payments.

How XOMA shareholders could benefit

XOMA shareholders could benefit from the acquisition of Ixinity’s commercial payment and milestone rights, as it is expected to generate consistent quarterly payments. Sitko highlighted two main growth areas for Ixinity: expanding the label to include the pediatric population, which could increase the market opportunity by up to 33%, and obtaining approval for the Canadian market. The new commercial payment stream will build consistent incoming cash flow, and the established niche in Hemophilia B treatment offers potential growth opportunities.

XOMA has a portfolio of more than 70 assets. The company provides non-dilutive, non-recourse funding to advance internal drug candidates or for general corporate purposes. Other examples of biotech royalty aggregators include Royalty Pharma (Nasdaq:RPRX) and DRI Healthcare (TSE:DHT.UN).


Filed Under: Biologics, Hematology
Tagged With: Aptevo Therapeutics, biotech, Ixinity, royalty aggregator, XOMA
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
FDA approved ENFLONSIA for the prevention of RSV in Infants
Sanofi ramps up distribution of Beyfortus ahead of RSV season
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE